For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
The price of Denali Therapeutics Inc (NASDAQ: DNLI) closed at $16.31 in the last session, up 7.23% from day before closing price of $15.21. In other words, the price has increased by $7.23 from its previous closing price. On the day, 1.7 million shares were traded. DNLI stock price reached its highest trading level at $16.43 during the session, while it also had its lowest trading level at $15.19.
Ratios:
We take a closer look at DNLI’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 10.27 and its Current Ratio is at 10.27. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.04.
On February 11, 2025, Deutsche Bank started tracking the stock assigning a Buy rating and target price of $31.Deutsche Bank initiated its Buy rating on February 11, 2025, with a $31 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 12 ’25 when Schuth Alexander O. sold 2,937 shares for $13.58 per share. The transaction valued at 39,884 led to the insider holds 242,346 shares of the business.
Ho Carole sold 2,937 shares of DNLI for $39,884 on Aug 12 ’25. The Chief Medical Officer now owns 217,391 shares after completing the transaction at $13.58 per share. On Aug 13 ’25, another insider, Ho Carole, who serves as the Chief Medical Officer of the company, sold 806 shares for $14.64 each. As a result, the insider received 11,800 and left with 216,585 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DNLI now has a Market Capitalization of 2384722176 and an Enterprise Value of 1533743232.
Stock Price History:
The Beta on a monthly basis for DNLI is 1.37, which has changed by -0.4452954 over the last 52 weeks, in comparison to a change of 0.14201736 over the same period for the S&P500. Over the past 52 weeks, DNLI has reached a high of $33.33, while it has fallen to a 52-week low of $10.57. The 50-Day Moving Average of the stock is 11.31%, while the 200-Day Moving Average is calculated to be 2.82%.
Shares Statistics:
According to the various share statistics, DNLI traded on average about 1.94M shares per day over the past 3-months and 1723070 shares per day over the past 10 days. A total of 145.69M shares are outstanding, with a floating share count of 130.83M. Insiders hold about 10.52% of the company’s shares, while institutions hold 94.44% stake in the company. Shares short for DNLI as of 1759190400 were 14150041 with a Short Ratio of 7.29, compared to 1756425600 on 13746176. Therefore, it implies a Short% of Shares Outstanding of 14150041 and a Short% of Float of 10.83.
Earnings Estimates
The stock of Denali Therapeutics Inc (DNLI) is currently drawing attention from 15.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$0.77, with high estimates of -$0.38 and low estimates of -$0.95.
Analysts are recommending an EPS of between -$2.64 and -$3.33 for the fiscal current year, implying an average EPS of -$3.03. EPS for the following year is -$2.83, with 14.0 analysts recommending between -$1.81 and -$3.68.
Revenue Estimates
Based on 18 analysts’ estimates, the company’s revenue will be $85.98M in the next fiscal year. The high estimate is $278.66M and the low estimate is $9.56M.
